Janssen’s Invokana became the only medicine in nearly 20 years and the first diabetes medicine ever to demonstrate a reduction in progression to end-stage renal failure in T2D patients with CKD.
Sumitomo Dainippon Pharma Co. Ltd. and Poxel SA announced the signing of a strategic partnership for the development and commercialization of Imeglimin – an investigational therapeutic agent for type 2 diabetes – in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries. Poxel is a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders.
Concerted effort by governments, regulators, and industry is rapidly expanding development of new therapies for the more than 7,000 known rare diseases.
